|
Primary Care Network designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Target Audience:
This activity is targeted to all physicians and other healthcare professionals who treat patients with HPV.
Original Release date: February 15, 2007
Rereleased: February 14, 2008
Expiration date: February 14, 2009
Acknowledgement of Commercial Support:
This activity is funded by Primary Care Network.
Post-test and Evaluation
In order to receive CME credit, you will need to complete the post-test. Upon successful completion of the post-test, you will be asked to fill out a program evaluation form and prompted to print your CME certificate.
Content Developers & Disclosures
Gregory Brotzman, MD - speaker
Edward John Mayeaux, JR, MD, DABFP, FAAFP - speaker
Program Overview:
Genital human papillomavirus (HPV), the most common sexually transmitted infection (STI), is the etiologic agent responsible for cervical cancer and other anogenital cancers, most low- and high-grade cervical lesions, and genital warts. Multivalent vaccines that protect against the most common disease-causing HPV types are in final stages of clinical testing and have demonstrated promising results. Phase 2 trials of a bivalent vaccine that is formulated to protect against the two most common cervical cancer-causing HPV types (HPV 16 and 18) have shown that vaccination is 100% effective in preventing persistent HPV 16 and 18 infections. A quadrivalent vaccine, which also protects against these oncogenic types, adds protection against the two most common genital wart causing HPV types (HPV 6 and 11). Phase 2 studies demonstrated that this vaccine was highly effective at preventing persistent infection with these HPV types and preliminary results from ongoing phase 3 efficacy studies have shown that the quadrivalent vaccine is 100% efficacious in preventing HPV 16- and 18-associated cervical cancer, adenocarcinoma in situ, and cervical intraepithelial neoplasia. Together, these reports suggest that widespread vaccination against HPV has the potential to reduce the incidence of HPV infection and HPV-related disease, as well as lessen the emotional and economic burden associated with HPV infection.
Learning Objectives
After completing this activity, the participant will be able to:
- Identify the link between HPV infection and cervical cancer and HPV infection and genital warts
- Review late stage clinical findings of preventive HPV vaccines
When finished, click here to take the Post-test
Take the post-test to receive your CME certificate
|
